Table 3.
Age-standardised country-specific seroprevalences of antibodies against 10 ToRCH pathogens were calculated based on samples with available age information (n = 984) and reported as mean percentage and 95% confidence interval. Mean and standard deviation (s.d.) across countries for each pathogen were calculated based on all available samples (n = 1009).
| Pathogen | Mexico | Brazil | Germany | Poland | Turkey | China | Mean | Standard deviation |
|---|---|---|---|---|---|---|---|---|
| Seroprevalence of IgG antibodies against | ||||||||
| T. gondii | 31.4 (6.4–56.3) | 56.2 (45.6–66.9) | 39.5 (13.5–65.6) | 22.3 (7.2–37.4) | 34.7 (10.3–59.2) | 0.5 (0.0–1.4) | 27.2 | 18.5 |
| Rubella virus | 99.0 (96.6–100.0) | 97.4 (94.3–100.0) | 97.9 (95.2–100.0) | 99.8 (99.2–100.0) | 94.1 (86.1–100.0) | 83.2 (65.7–100.0) | 96.3 | 3.3 |
| CMV | 79.9 (68.2–91.5) | 98.1 (94.6–100.0) | 28.3 (10.3–46.3) | 68.8 (51.5–86.0) | 98.4 (93.9–100.0) | 91.9 (84.3–99.6) | 77.3 | 23.7 |
| HSV1 | 75.6 (60.3–90.8) | 95.7 (92.5–98.8) | 62.5 (36.5–88.4) | 85.7 (70.3–100.0) | 94.7 (87.7–100.0) | 87.9 (79.1–96.7) | 85.1 | 8.0 |
| HSV2 | 10.7 (0.0–21.5) | 40.1 (27.5–52.7) | 8.3 (0.0–17.3) | 4.1 (0.0–9.3) | 2.1 (0.0–6.5) | 7.2 (0.7–13.6) | 13.4 | 13.5 |
| B. pertussis | 0.7 (0.0–2.5) | 56.6 (47.3–66.0) | 22.2 (0.0–46.9) | 1.2 (0.0–3.2) | 1.6 (0.0–6.1) | 0.2 (0.0–0.8) | 13.3 | 23.3 |
| C. trachomatis | 14.8 (6.1–23.5) | 46.8 (40.5–53.0) | 10.9 (3.8–18.0) | 7.4 (0.0–15.9) | 13.9 (0.0–31.6) | 18.8 (4.5–33.1) | 18.8 | 15.2 |
| Parvovirus B19 | 50.1 (37.6–62.5) | 31.1 (17.6–44.7) | 46.7 (28.1–65.4) | 65.1 (40.6–89.6) | 50.6 (36.2–64.9) | 7.7 (1.1–14.4) | 42.2 | 16.5 |
| T. pallidum | 1.4 (0.0–3.7) | 0.9 (0.0–2.2) | 1.1 (0.0–2.4) | 1.7 (0.0–5.0) | 2.3 (0.0–7.1) | 1.0 (0.0–2.2) | 1.7 | 0.7 |
| VZV | 98.7 (95.4–100.0) | 94.5 (88.6–100.0) | 99.4 (98.1–100.0) | 98.1 (95.7–100.0) | 98.6 (96.2–100.0) | 92.3 (84.5–100.0) | 95.9 | 3.7 |